<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 14 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:inherit;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
h1
	{mso-style-link:"Heading 1 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:24.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:18.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:13.5pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:8.0pt;
	font-family:"Tahoma","sans-serif";}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-button, li.ui-button, div.ui-button
	{mso-style-name:ui-button;
	margin-right:1.2pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner, li.ui-spinner, div.ui-spinner
	{mso-style-name:ui-spinner;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner-input, li.ui-spinner-input, div.ui-spinner-input
	{mso-style-name:ui-spinner-input;
	margin-top:2.4pt;
	margin-right:16.5pt;
	margin-bottom:2.4pt;
	margin-left:4.8pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-hidden-accessible, li.ui-helper-hidden-accessible, div.ui-helper-hidden-accessible
	{mso-style-name:ui-helper-hidden-accessible;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-buttonset, li.ui-buttonset, div.ui-buttonset
	{mso-style-name:ui-buttonset;
	margin-right:5.25pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker, li.ui-datepicker, div.ui-datepicker
	{mso-style-name:ui-datepicker;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-datepicker-row-break, li.ui-datepicker-row-break, div.ui-datepicker-row-break
	{mso-style-name:ui-datepicker-row-break;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-rtl, li.ui-datepicker-rtl, div.ui-datepicker-rtl
	{mso-style-name:ui-datepicker-rtl;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	direction:rtl;
	unicode-bidi:embed;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu, li.ui-menu, div.ui-menu
	{mso-style-name:ui-menu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar, li.ui-progressbar, div.ui-progressbar
	{mso-style-name:ui-progressbar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-handle, li.ui-resizable-handle, div.ui-resizable-handle
	{mso-style-name:ui-resizable-handle;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-n, li.ui-resizable-n, div.ui-resizable-n
	{mso-style-name:ui-resizable-n;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-s, li.ui-resizable-s, div.ui-resizable-s
	{mso-style-name:ui-resizable-s;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-e, li.ui-resizable-e, div.ui-resizable-e
	{mso-style-name:ui-resizable-e;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-w, li.ui-resizable-w, div.ui-resizable-w
	{mso-style-name:ui-resizable-w;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-se, li.ui-resizable-se, div.ui-resizable-se
	{mso-style-name:ui-resizable-se;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-sw, li.ui-resizable-sw, div.ui-resizable-sw
	{mso-style-name:ui-resizable-sw;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-nw, li.ui-resizable-nw, div.ui-resizable-nw
	{mso-style-name:ui-resizable-nw;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-ne, li.ui-resizable-ne, div.ui-resizable-ne
	{mso-style-name:ui-resizable-ne;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectable-helper, li.ui-selectable-helper, div.ui-selectable-helper
	{mso-style-name:ui-selectable-helper;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-menu, li.ui-selectmenu-menu, div.ui-selectmenu-menu
	{mso-style-name:ui-selectmenu-menu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-selectmenu-open, li.ui-selectmenu-open, div.ui-selectmenu-open
	{mso-style-name:ui-selectmenu-open;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-button, li.ui-selectmenu-button, div.ui-selectmenu-button
	{mso-style-name:ui-selectmenu-button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider, li.ui-slider, div.ui-slider
	{mso-style-name:ui-slider;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-horizontal, li.ui-slider-horizontal, div.ui-slider-horizontal
	{mso-style-name:ui-slider-horizontal;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-vertical, li.ui-slider-vertical, div.ui-slider-vertical
	{mso-style-name:ui-slider-vertical;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner-button, li.ui-spinner-button, div.ui-spinner-button
	{mso-style-name:ui-spinner-button;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:6.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tooltip, li.ui-tooltip, div.ui-tooltip
	{mso-style-name:ui-tooltip;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-default, li.ui-state-default, div.ui-state-default
	{mso-style-name:ui-state-default;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-focus, li.ui-state-focus, div.ui-state-focus
	{mso-style-name:ui-state-focus;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover, li.ui-state-hover, div.ui-state-hover
	{mso-style-name:ui-state-hover;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active, li.ui-state-active, div.ui-state-active
	{mso-style-name:ui-state-active;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-highlight, li.ui-state-highlight, div.ui-state-highlight
	{mso-style-name:ui-state-highlight;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-error, li.ui-state-error, div.ui-state-error
	{mso-style-name:ui-state-error;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text, li.ui-state-error-text, div.ui-state-error-text
	{mso-style-name:ui-state-error-text;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-priority-primary, li.ui-priority-primary, div.ui-priority-primary
	{mso-style-name:ui-priority-primary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-secondary, li.ui-priority-secondary, div.ui-priority-secondary
	{mso-style-name:ui-priority-secondary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled, li.ui-state-disabled, div.ui-state-disabled
	{mso-style-name:ui-state-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-hidden, li.ui-helper-hidden, div.ui-helper-hidden
	{mso-style-name:ui-helper-hidden;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-helper-reset, li.ui-helper-reset, div.ui-helper-reset
	{mso-style-name:ui-helper-reset;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-zfix, li.ui-helper-zfix, div.ui-helper-zfix
	{mso-style-name:ui-helper-zfix;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget-overlay, li.ui-widget-overlay, div.ui-widget-overlay
	{mso-style-name:ui-widget-overlay;
	margin-right:0in;
	margin-left:0in;
	background:#AAAAAA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-clearfix, li.ui-helper-clearfix, div.ui-helper-clearfix
	{mso-style-name:ui-helper-clearfix;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon, li.ui-icon, div.ui-icon
	{mso-style-name:ui-icon;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget-content, li.ui-widget-content, div.ui-widget-content
	{mso-style-name:ui-widget-content;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#222222;}
p.ui-widget-header, li.ui-widget-header, div.ui-widget-header
	{mso-style-name:ui-widget-header;
	margin-right:0in;
	margin-left:0in;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#222222;
	font-weight:bold;}
p.ui-widget-shadow, li.ui-widget-shadow, div.ui-widget-shadow
	{mso-style-name:ui-widget-shadow;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:-6.0pt;
	margin-bottom:.0001pt;
	background:#AAAAAA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget, li.ui-widget, div.ui-widget
	{mso-style-name:ui-widget;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.ui-tabs, li.ui-tabs, div.ui-tabs
	{mso-style-name:ui-tabs;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog, li.ui-dialog, div.ui-dialog
	{mso-style-name:ui-dialog;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-titlebar, li.ui-dialog-titlebar, div.ui-dialog-titlebar
	{mso-style-name:ui-dialog-titlebar;
	margin-right:0in;
	margin-left:0in;
	background:#3E72A6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.ui-ncbiautocomplete-actions, li.ui-ncbiautocomplete-actions, div.ui-ncbiautocomplete-actions
	{mso-style-name:ui-ncbiautocomplete-actions;
	margin-top:.75pt;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:#CECECE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref, li.ui-ncbiautocomplete-link-pref, div.ui-ncbiautocomplete-link-pref
	{mso-style-name:ui-ncbiautocomplete-link-pref;
	margin-right:0in;
	margin-left:0in;
	text-indent:-945.65pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton, li.ui-ncbibutton, div.ui-ncbibutton
	{mso-style-name:ui-ncbibutton;
	margin-right:1.2pt;
	margin-left:0in;
	text-align:center;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"inherit","serif";}
p.ui-button-icon-only, li.ui-button-icon-only, div.ui-button-icon-only
	{mso-style-name:ui-button-icon-only;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icons-only, li.ui-button-icons-only, div.ui-button-icons-only
	{mso-style-name:ui-button-icons-only;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-outer-div, li.ui-ncbigrid-outer-div, div.ui-ncbigrid-outer-div
	{mso-style-name:ui-ncbigrid-outer-div;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:33.6pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-inner-div, li.ui-ncbigrid-inner-div, div.ui-ncbigrid-inner-div
	{mso-style-name:ui-ncbigrid-inner-div;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-filter-toolbar, li.ui-ncbigrid-filter-toolbar, div.ui-ncbigrid-filter-toolbar
	{mso-style-name:ui-ncbigrid-filter-toolbar;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	line-height:20.25pt;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-toolbar, li.ui-ncbigrid-paged-toolbar, div.ui-ncbigrid-paged-toolbar
	{mso-style-name:ui-ncbigrid-paged-toolbar;
	margin-right:0in;
	margin-left:0in;
	line-height:19.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-checkbox-toolbar, li.ui-ncbigrid-checkbox-toolbar, div.ui-ncbigrid-checkbox-toolbar
	{mso-style-name:ui-ncbigrid-checkbox-toolbar;
	margin-right:0in;
	margin-left:0in;
	line-height:21.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-countitems, li.ui-ncbigrid-paged-countitems, div.ui-ncbigrid-paged-countitems
	{mso-style-name:ui-ncbigrid-paged-countitems;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-pagecontrol, li.ui-ncbigrid-paged-pagecontrol, div.ui-ncbigrid-paged-pagecontrol
	{mso-style-name:ui-ncbigrid-paged-pagecontrol;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-toolbar-bottom, li.ui-ncbigrid-paged-toolbar-bottom, div.ui-ncbigrid-paged-toolbar-bottom
	{mso-style-name:ui-ncbigrid-paged-toolbar-bottom;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-question, li.ui-ncbigrid-select-question, div.ui-ncbigrid-select-question
	{mso-style-name:ui-ncbigrid-select-question;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbigrid-select-question-footer, li.ui-ncbigrid-select-question-footer, div.ui-ncbigrid-select-question-footer
	{mso-style-name:ui-ncbigrid-select-question-footer;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenu, li.ui-ncbibasicmenu, div.ui-ncbibasicmenu
	{mso-style-name:ui-ncbibasicmenu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenuli, li.ui-ncbibasicmenuli, div.ui-ncbibasicmenuli
	{mso-style-name:ui-ncbibasicmenu>li;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.orientationhortli, li.orientationhortli, div.orientationhortli
	{mso-style-name:orientation_hort>li;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbimenu, li.jig-ncbimenu, div.jig-ncbimenu
	{mso-style-name:jig-ncbimenu;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbimenuli, li.jig-ncbimenuli, div.jig-ncbimenuli
	{mso-style-name:jig-ncbimenu>li;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbipopper-wrapper, li.ui-ncbipopper-wrapper, div.ui-ncbipopper-wrapper
	{mso-style-name:ui-ncbipopper-wrapper;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbipopper-basic, li.ui-ncbipopper-basic, div.ui-ncbipopper-basic
	{mso-style-name:ui-ncbipopper-basic;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#303030;}
p.brieflinkpopdesc, li.brieflinkpopdesc, div.brieflinkpopdesc
	{mso-style-name:brieflinkpopdesc;
	margin-top:4.8pt;
	margin-right:0in;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbitoggler-slave, li.ui-ncbitoggler-slave, div.ui-ncbitoggler-slave
	{mso-style-name:ui-ncbitoggler-slave;
	margin-top:2.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbitoggler-slave-open, li.ui-ncbitoggler-slave-open, div.ui-ncbitoggler-slave-open
	{mso-style-name:ui-ncbitoggler-slave-open;
	margin-top:2.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbilinksmenu, li.ui-ncbilinksmenu, div.ui-ncbilinksmenu
	{mso-style-name:ui-ncbilinksmenu;
	margin-right:0in;
	margin-left:0in;
	background:#FCFCFC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#999999;
	font-weight:bold;}
p.ui-ncbilinksmenu-loadingmessage, li.ui-ncbilinksmenu-loadingmessage, div.ui-ncbilinksmenu-loadingmessage
	{mso-style-name:ui-ncbilinksmenu-loadingmessage;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiclearbutton-wrap, li.ui-ncbiclearbutton-wrap, div.ui-ncbiclearbutton-wrap
	{mso-style-name:ui-ncbiclearbutton-wrap;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiexpander, li.ui-ncbiexpander, div.ui-ncbiexpander
	{mso-style-name:ui-ncbiexpander;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiexpander-simple, li.ui-ncbiexpander-simple, div.ui-ncbiexpander-simple
	{mso-style-name:ui-ncbiexpander-simple;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-expander-arrow-bar, li.ui-expander-arrow-bar, div.ui-expander-arrow-bar
	{mso-style-name:ui-expander-arrow-bar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-expander-controllink, li.ui-expander-controllink, div.ui-expander-controllink
	{mso-style-name:ui-expander-controllink;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbiinpagenav-goto-container, li.jig-ncbiinpagenav-goto-container, div.jig-ncbiinpagenav-goto-container
	{mso-style-name:jig-ncbiinpagenav-goto-container;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch, li.ui-ncbisetswitch, div.ui-ncbisetswitch
	{mso-style-name:ui-ncbisetswitch;
	margin-right:0in;
	margin-left:0in;
	background:#F6F6F6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;}
p.ui-ncbisetswitch-hasstar, li.ui-ncbisetswitch-hasstar, div.ui-ncbisetswitch-hasstar
	{mso-style-name:ui-ncbisetswitch-hasstar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fg-button-icon-left, li.fg-button-icon-left, div.fg-button-icon-left
	{mso-style-name:fg-button-icon-left;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbihistogram, li.jig-ncbihistogram, div.jig-ncbihistogram
	{mso-style-name:jig-ncbihistogram;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram, li.ui-ncbihistogram, div.ui-ncbihistogram
	{mso-style-name:ui-ncbihistogram;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-display-area, li.ui-ncbihistogram-display-area, div.ui-ncbihistogram-display-area
	{mso-style-name:ui-ncbihistogram-display-area;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-display-areaollih3, li.ui-ncbihistogram-display-areaollih3, div.ui-ncbihistogram-display-areaollih3
	{mso-style-name:ui-ncbihistogram-display-area>ol>li>h3;
	margin:0in;
	margin-bottom:.0001pt;
	text-indent:366.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-controls, li.ui-ncbihistogram-controls, div.ui-ncbihistogram-controls
	{mso-style-name:ui-ncbihistogram-controls;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-left, li.ui-ncbihistogram-left, div.ui-ncbihistogram-left
	{mso-style-name:ui-ncbihistogram-left;
	margin-right:0in;
	margin-left:2.25pt;
	text-align:center;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-right, li.ui-ncbihistogram-right, div.ui-ncbihistogram-right
	{mso-style-name:ui-ncbihistogram-right;
	margin-right:2.25pt;
	margin-left:0in;
	text-align:center;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-left-disabled, li.ui-ncbihistogram-left-disabled, div.ui-ncbihistogram-left-disabled
	{mso-style-name:ui-ncbihistogram-left-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#DDDDDD;}
p.ui-ncbihistogram-right-disabled, li.ui-ncbihistogram-right-disabled, div.ui-ncbihistogram-right-disabled
	{mso-style-name:ui-ncbihistogram-right-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#DDDDDD;}
p.ui-ncbihistogram-text, li.ui-ncbihistogram-text, div.ui-ncbihistogram-text
	{mso-style-name:ui-ncbihistogram-text;
	margin-top:0in;
	margin-right:12.75pt;
	margin-bottom:0in;
	margin-left:12.75pt;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:21.8pt;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-tooltip, li.ui-ncbihistogram-tooltip, div.ui-ncbihistogram-tooltip
	{mso-style-name:ui-ncbihistogram-tooltip;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	display:none;}
p.ncbiactivevalidationmsg, li.ncbiactivevalidationmsg, div.ncbiactivevalidationmsg
	{mso-style-name:ncbiactivevalidation_msg;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ncbiactivevalidationmsgchecking, li.ncbiactivevalidationmsgchecking, div.ncbiactivevalidationmsgchecking
	{mso-style-name:ncbiactivevalidation_msg_checking;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#FF9900;}
p.ncbiactivevalidationmsgvalid, li.ncbiactivevalidationmsgvalid, div.ncbiactivevalidationmsgvalid
	{mso-style-name:ncbiactivevalidation_msg_valid;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:green;}
p.ncbiactivevalidationmsgerror, li.ncbiactivevalidationmsgerror, div.ncbiactivevalidationmsgerror
	{mso-style-name:ncbiactivevalidation_msg_error;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.ncbiactivevalidationmsginfo, li.ncbiactivevalidationmsginfo, div.ncbiactivevalidationmsginfo
	{mso-style-name:ncbiactivevalidation_msg_info;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:blue;}
p.ncbiactivevalidationelerror, li.ncbiactivevalidationelerror, div.ncbiactivevalidationelerror
	{mso-style-name:ncbiactivevalidation_el_error;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.social-buttons, li.social-buttons, div.social-buttons
	{mso-style-name:social-buttons;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.inlinelist, li.inlinelist, div.inlinelist
	{mso-style-name:inline_list;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.inline, li.inline, div.inline
	{mso-style-name:inline;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fig, li.fig, div.fig
	{mso-style-name:fig;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.table, li.table, div.table
	{mso-style-name:table;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pmc-wm, li.pmc-wm, div.pmc-wm
	{mso-style-name:pmc-wm;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.attic, li.attic, div.attic
	{mso-style-name:attic;
	margin-right:0in;
	margin-left:0in;
	background:#336699;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.basement, li.basement, div.basement
	{mso-style-name:basement;
	margin-right:0in;
	margin-left:0in;
	background:#336699;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-breadcrumbs, li.page-breadcrumbs, div.page-breadcrumbs
	{mso-style-name:page-breadcrumbs;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.first-line-outdent, li.first-line-outdent, div.first-line-outdent
	{mso-style-name:first-line-outdent;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vatop, li.vatop, div.vatop
	{mso-style-name:va_top;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vamiddle, li.vamiddle, div.vamiddle
	{mso-style-name:va_middle;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.qtrhythm, li.qtrhythm, div.qtrhythm
	{mso-style-name:qt_rhythm;
	margin-top:4.15pt;
	margin-right:0in;
	margin-bottom:4.15pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notopmargin, li.notopmargin, div.notopmargin
	{mso-style-name:no_top_margin;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nobottommargin, li.nobottommargin, div.nobottommargin
	{mso-style-name:no_bottom_margin;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tscanvas, li.tscanvas, div.tscanvas
	{mso-style-name:ts_canvas;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tsbar, li.tsbar, div.tsbar
	{mso-style-name:ts_bar;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#DCF0F4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-reuse, li.fm-reuse, div.fm-reuse
	{mso-style-name:fm-reuse;
	margin-right:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-subtitle, li.fm-subtitle, div.fm-subtitle
	{mso-style-name:fm-subtitle;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:15.0pt;
	font-family:"Times New Roman","serif";}
p.fm-copyright-license, li.fm-copyright-license, div.fm-copyright-license
	{mso-style-name:fm-copyright-license;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-citation-from, li.fm-citation-from, div.fm-citation-from
	{mso-style-name:fm-citation-from;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ft-thumb-box, li.ft-thumb-box, div.ft-thumb-box
	{mso-style-name:ft-thumb-box;
	margin:8.3pt;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ft-thumb-current, li.ft-thumb-current, div.ft-thumb-current
	{mso-style-name:ft-thumb-current;
	margin-right:0in;
	margin-left:0in;
	background:#D0DCE8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tab, li.tab, div.tab
	{mso-style-name:tab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.arrowtab, li.arrowtab, div.arrowtab
	{mso-style-name:arrowtab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.blanktab, li.blanktab, div.blanktab
	{mso-style-name:blanktab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.thistab, li.thistab, div.thistab
	{mso-style-name:thistab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	font-weight:bold;}
p.doi, li.doi, div.doi
	{mso-style-name:doi;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.msg-error, li.msg-error, div.msg-error
	{mso-style-name:msg-error;
	margin-right:0in;
	margin-left:0in;
	background:yellow;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.msg-warning, li.msg-warning, div.msg-warning
	{mso-style-name:msg-warning;
	margin-right:0in;
	margin-left:0in;
	background:yellow;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:brown;}
p.nihms-highlight, li.nihms-highlight, div.nihms-highlight
	{mso-style-name:nihms-highlight;
	margin-top:0in;
	margin-right:2.4pt;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:center;
	background:yellow;
	font-size:10.5pt;
	font-family:"Times New Roman","serif";
	color:#990000;}
p.head, li.head, div.head
	{mso-style-name:head;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sub-head, li.sub-head, div.sub-head
	{mso-style-name:sub-head;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.headless, li.headless, div.headless
	{mso-style-name:headless;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sub-navigation, li.sub-navigation, div.sub-navigation
	{mso-style-name:sub-navigation;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sec, li.sec, div.sec
	{mso-style-name:sec;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content-branding, li.content-branding, div.content-branding
	{mso-style-name:content-branding;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-generic-logo-background, li.banner-generic-logo-background, div.banner-generic-logo-background
	{mso-style-name:banner-generic-logo-background;
	margin-right:0in;
	margin-left:0in;
	background:silver;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.banner-journal-name, li.banner-journal-name, div.banner-journal-name
	{mso-style-name:banner-journal-name;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:20.5pt;
	font-family:"Calibri","sans-serif";
	font-variant:small-caps;
	letter-spacing:.3pt;}
p.banner-journal-publisher-over-image, li.banner-journal-publisher-over-image, div.banner-journal-publisher-over-image
	{mso-style-name:banner-journal-publisher-over-image;
	margin-right:7.5pt;
	margin-left:63.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-publisher-name, li.banner-publisher-name, div.banner-publisher-name
	{mso-style-name:banner-publisher-name;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:9.5pt;
	font-family:"Calibri","sans-serif";
	color:#AA1111;
	font-weight:bold;}
p.bl-w-jtitle-over, li.bl-w-jtitle-over, div.bl-w-jtitle-over
	{mso-style-name:bl-w-jtitle-over;
	margin-right:0in;
	margin-left:0in;
	font-size:18.0pt;
	font-family:"Times New Roman","serif";
	font-variant:small-caps;}
p.bl-w-jtitle-over-ph, li.bl-w-jtitle-over-ph, div.bl-w-jtitle-over-ph
	{mso-style-name:bl-w-jtitle-over-ph;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-w-jtitle-over-ph-content, li.bl-w-jtitle-over-ph-content, div.bl-w-jtitle-over-ph-content
	{mso-style-name:bl-w-jtitle-over-ph-content;
	margin-top:3.0pt;
	margin-right:6.0pt;
	margin-bottom:3.0pt;
	margin-left:78.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-journal-publisher-over-image-elsevierwt, li.banner-journal-publisher-over-image-elsevierwt, div.banner-journal-publisher-over-image-elsevierwt
	{mso-style-name:banner-journal-publisher-over-image-elsevierwt;
	margin-top:0in;
	margin-right:120.0pt;
	margin-bottom:0in;
	margin-left:15.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.elsevierwt-sponsored-label, li.elsevierwt-sponsored-label, div.elsevierwt-sponsored-label
	{mso-style-name:elsevierwt-sponsored-label;
	margin-right:0in;
	margin-left:-9.0pt;
	line-height:13.5pt;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	font-variant:small-caps;
	letter-spacing:.9pt;
	font-style:italic;}
p.bl-jtitle-sageopen, li.bl-jtitle-sageopen, div.bl-jtitle-sageopen
	{mso-style-name:bl-jtitle-sageopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#0055A5;}
p.bl-jtitle-iospressopenlib, li.bl-jtitle-iospressopenlib, div.bl-jtitle-iospressopenlib
	{mso-style-name:bl-jtitle-iospressopenlib;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-apasd, li.bl-jtitle-apasd, div.bl-jtitle-apasd
	{mso-style-name:bl-jtitle-apasd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#1E73B3;}
p.bl-jtitle-springeropen, li.bl-jtitle-springeropen, div.bl-jtitle-springeropen
	{mso-style-name:bl-jtitle-springeropen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#F0F0F0;}
p.bl-jtitle-sfesd, li.bl-jtitle-sfesd, div.bl-jtitle-sfesd
	{mso-style-name:bl-jtitle-sfesd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-acssd, li.bl-jtitle-acssd, div.bl-jtitle-acssd
	{mso-style-name:bl-jtitle-acssd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#1E73B3;}
p.bl-jtitle-esesd, li.bl-jtitle-esesd, div.bl-jtitle-esesd
	{mso-style-name:bl-jtitle-esesd;
	margin-right:0in;
	margin-left:0in;
	line-height:33.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-jtitle-srfsd, li.bl-jtitle-srfsd, div.bl-jtitle-srfsd
	{mso-style-name:bl-jtitle-srfsd;
	margin-right:0in;
	margin-left:0in;
	line-height:33.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-jtitle-tea, li.bl-jtitle-tea, div.bl-jtitle-tea
	{mso-style-name:bl-jtitle-tea;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#861316;}
p.bl-jtitle-rcpsychsd, li.bl-jtitle-rcpsychsd, div.bl-jtitle-rcpsychsd
	{mso-style-name:bl-jtitle-rcpsychsd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#44448A;}
p.bl-jtitle-npgopen, li.bl-jtitle-npgopen, div.bl-jtitle-npgopen
	{mso-style-name:bl-jtitle-npgopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-maneyopen, li.bl-jtitle-maneyopen, div.bl-jtitle-maneyopen
	{mso-style-name:bl-jtitle-maneyopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-bmjgroup, li.bl-jtitle-bmjgroup, div.bl-jtitle-bmjgroup
	{mso-style-name:bl-jtitle-bmjgroup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#003366;}
p.bl-jtitle-clpt, li.bl-jtitle-clpt, div.bl-jtitle-clpt
	{mso-style-name:bl-jtitle-clpt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-nihpa-wiley, li.bl-jtitle-nihpa-wiley, div.bl-jtitle-nihpa-wiley
	{mso-style-name:bl-jtitle-nihpa-wiley;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-rsmsd, li.bl-jtitle-rsmsd, div.bl-jtitle-rsmsd
	{mso-style-name:bl-jtitle-rsmsd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-hogrefesd, li.bl-jtitle-hogrefesd, div.bl-jtitle-hogrefesd
	{mso-style-name:bl-jtitle-hogrefesd;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#025490;}
p.mp-outer, li.mp-outer, div.mp-outer
	{mso-style-name:mp-outer;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mp-outerdiv, li.mp-outerdiv, div.mp-outerdiv
	{mso-style-name:mp-outer>div;
	margin:1.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-highlight1, li.toc-highlight1, div.toc-highlight1
	{mso-style-name:toc-highlight1;
	margin-right:0in;
	margin-left:0in;
	background:#FFFFD0;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-highlight2, li.toc-highlight2, div.toc-highlight2
	{mso-style-name:toc-highlight2;
	margin-right:0in;
	margin-left:0in;
	background:#ACE4FF;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-hl-inaugural, li.toc-hl-inaugural, div.toc-hl-inaugural
	{mso-style-name:toc-hl-inaugural;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#E64A00;}
p.courtesy-note, li.courtesy-note, div.courtesy-note
	{mso-style-name:courtesy-note;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.footer, li.footer, div.footer
	{mso-style-name:footer;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.suppmat, li.suppmat, div.suppmat
	{mso-style-name:suppmat;
	margin-top:8.3pt;
	margin-right:0in;
	margin-bottom:8.3pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.aligncenter, li.aligncenter, div.aligncenter
	{mso-style-name:align_center;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mul-switcher, li.mul-switcher, div.mul-switcher
	{mso-style-name:mul-switcher;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.strong, li.strong, div.strong
	{mso-style-name:strong;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.red, li.red, div.red
	{mso-style-name:red;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.navigator, li.navigator, div.navigator
	{mso-style-name:navigator;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F6F6F6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.summary, li.summary, div.summary
	{mso-style-name:summary;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.head1a, li.head1a, div.head1a
	{mso-style-name:head1a;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-header, li.navigator-header, div.navigator-header
	{mso-style-name:navigator-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-footer, li.navigator-footer, div.navigator-footer
	{mso-style-name:navigator-footer;
	margin-top:7.5pt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-bar, li.navigator-bar, div.navigator-bar
	{mso-style-name:navigator-bar;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-page, li.navigator-page, div.navigator-page
	{mso-style-name:navigator-page;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-bar-table, li.navigator-bar-table, div.navigator-bar-table
	{mso-style-name:navigator-bar-table;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.section-with-images-on-the-same-page, li.section-with-images-on-the-same-page, div.section-with-images-on-the-same-page
	{mso-style-name:section-with-images-on-the-same-page;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.main-archive-list-of-volumes, li.main-archive-list-of-volumes, div.main-archive-list-of-volumes
	{mso-style-name:main-archive-list-of-volumes;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.archive-header, li.archive-header, div.archive-header
	{mso-style-name:archive-header;
	margin-right:0in;
	margin-bottom:7.5pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.journal-block-title, li.journal-block-title, div.journal-block-title
	{mso-style-name:journal-block-title;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#CCD8E4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	font-weight:bold;}
p.vol-year-cell, li.vol-year-cell, div.vol-year-cell
	{mso-style-name:vol-year-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#CCD8E4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	font-weight:bold;}
p.issue-block, li.issue-block, div.issue-block
	{mso-style-name:issue-block;
	margin-right:0in;
	margin-left:0in;
	background:#8CACCC;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-dark-row, li.iss-dark-row, div.iss-dark-row
	{mso-style-name:iss-dark-row;
	margin-right:0in;
	margin-left:0in;
	background:#EFF1F3;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-light-row, li.iss-light-row, div.iss-light-row
	{mso-style-name:iss-light-row;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-cell, li.iss-cell, div.iss-cell
	{mso-style-name:iss-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vol-cell, li.vol-cell, div.vol-cell
	{mso-style-name:vol-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.arc-issue, li.arc-issue, div.arc-issue
	{mso-style-name:arc-issue;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#0055AA;}
p.large-thumb-canvas, li.large-thumb-canvas, div.large-thumb-canvas
	{mso-style-name:large-thumb-canvas;
	margin:8.5pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;
	display:none;}
p.co, li.co, div.co
	{mso-style-name:co;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.co-default, li.co-default, div.co-default
	{mso-style-name:co-default;
	margin:8.5pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;}
p.large-thumb-canvas-1, li.large-thumb-canvas-1, div.large-thumb-canvas-1
	{mso-style-name:large-thumb-canvas-1;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.co-inner, li.co-inner, div.co-inner
	{mso-style-name:co-inner;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.in-progress, li.in-progress, div.in-progress
	{mso-style-name:in-progress;
	margin:1.5pt;
	background:#444444;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.large-thumb, li.large-thumb, div.large-thumb
	{mso-style-name:large-thumb;
	margin:1.5pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.small-thumb-canvas, li.small-thumb-canvas, div.small-thumb-canvas
	{mso-style-name:small-thumb-canvas;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.small-thumb, li.small-thumb, div.small-thumb
	{mso-style-name:small-thumb;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup-sensitive-area, li.figpopup-sensitive-area, div.figpopup-sensitive-area
	{mso-style-name:figpopup-sensitive-area;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.print-view, li.print-view, div.print-view
	{mso-style-name:print-view;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.citationexporter-header, li.citationexporter-header, div.citationexporter-header
	{mso-style-name:citationexporter-header;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-style:italic;}
p.citationexporter-footer, li.citationexporter-footer, div.citationexporter-footer
	{mso-style-name:citationexporter-footer;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxpreview, li.mathjaxpreview, div.mathjaxpreview
	{mso-style-name:mathjax_preview;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#888888;}
p.mathjaxerror, li.mathjaxerror, div.mathjaxerror
	{mso-style-name:mathjax_error;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CC0000;
	font-style:italic;}
p.mathjaxmenu, li.mathjaxmenu, div.mathjaxmenu
	{mso-style-name:mathjax_menu;
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;}
p.mathjaxmenuitem, li.mathjaxmenuitem, div.mathjaxmenuitem
	{mso-style-name:mathjax_menuitem;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxmenuarrow, li.mathjaxmenuarrow, div.mathjaxmenuarrow
	{mso-style-name:mathjax_menuarrow;
	margin-right:0in;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Arial Unicode MS","sans-serif";
	color:#666666;}
p.mathjaxmenucheck, li.mathjaxmenucheck, div.mathjaxmenucheck
	{mso-style-name:mathjax_menucheck;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS","sans-serif";}
p.mathjaxmenulabel, li.mathjaxmenulabel, div.mathjaxmenulabel
	{mso-style-name:mathjax_menulabel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-style:italic;}
p.mathjaxmenurule, li.mathjaxmenurule, div.mathjaxmenurule
	{mso-style-name:mathjax_menurule;
	margin-top:3.0pt;
	margin-right:.75pt;
	margin-bottom:0in;
	margin-left:.75pt;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxmenuclose, li.mathjaxmenuclose, div.mathjaxmenuclose
	{mso-style-name:mathjax_menuclose;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:18.0pt;
	font-family:"Courier New";
	color:#F0F0F0;}
p.print-log, li.print-log, div.print-log
	{mso-style-name:print-log;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header, li.ui-accordion-header, div.ui-accordion-header
	{mso-style-name:ui-accordion-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons, li.ui-accordion-icons, div.ui-accordion-icons
	{mso-style-name:ui-accordion-icons;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-content, li.ui-accordion-content, div.ui-accordion-content
	{mso-style-name:ui-accordion-content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text, li.ui-button-text, div.ui-button-text
	{mso-style-name:ui-button-text;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header, li.ui-datepicker-header, div.ui-datepicker-header
	{mso-style-name:ui-datepicker-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-next, li.ui-datepicker-next, div.ui-datepicker-next
	{mso-style-name:ui-datepicker-next;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-prev, li.ui-datepicker-prev, div.ui-datepicker-prev
	{mso-style-name:ui-datepicker-prev;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-title, li.ui-datepicker-title, div.ui-datepicker-title
	{mso-style-name:ui-datepicker-title;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane, li.ui-datepicker-buttonpane, div.ui-datepicker-buttonpane
	{mso-style-name:ui-datepicker-buttonpane;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group, li.ui-datepicker-group, div.ui-datepicker-group
	{mso-style-name:ui-datepicker-group;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-title, li.ui-dialog-title, div.ui-dialog-title
	{mso-style-name:ui-dialog-title;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-buttonpane, li.ui-dialog-buttonpane, div.ui-dialog-buttonpane
	{mso-style-name:ui-dialog-buttonpane;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-item, li.ui-menu-item, div.ui-menu-item
	{mso-style-name:ui-menu-item;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-divider, li.ui-menu-divider, div.ui-menu-divider
	{mso-style-name:ui-menu-divider;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value, li.ui-progressbar-value, div.ui-progressbar-value
	{mso-style-name:ui-progressbar-value;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-overlay, li.ui-progressbar-overlay, div.ui-progressbar-overlay
	{mso-style-name:ui-progressbar-overlay;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle, li.ui-slider-handle, div.ui-slider-handle
	{mso-style-name:ui-slider-handle;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range, li.ui-slider-range, div.ui-slider-range
	{mso-style-name:ui-slider-range;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-nav, li.ui-tabs-nav, div.ui-tabs-nav
	{mso-style-name:ui-tabs-nav;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-panel, li.ui-tabs-panel, div.ui-tabs-panel
	{mso-style-name:ui-tabs-panel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-hide, li.ui-tabs-hide, div.ui-tabs-hide
	{mso-style-name:ui-tabs-hide;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-titlebar-close, li.ui-dialog-titlebar-close, div.ui-dialog-titlebar-close
	{mso-style-name:ui-dialog-titlebar-close;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-content, li.ui-dialog-content, div.ui-dialog-content
	{mso-style-name:ui-dialog-content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref-right, li.ui-ncbiautocomplete-link-pref-right, div.ui-ncbiautocomplete-link-pref-right
	{mso-style-name:ui-ncbiautocomplete-link-pref-right;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary, li.ui-button-icon-primary, div.ui-button-icon-primary
	{mso-style-name:ui-button-icon-primary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary, li.ui-button-icon-secondary, div.ui-button-icon-secondary
	{mso-style-name:ui-button-icon-secondary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.prev, li.prev, div.prev
	{mso-style-name:prev;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.next, li.next, div.next
	{mso-style-name:next;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-row-count, li.ui-ncbigrid-select-row-count, div.ui-ncbigrid-select-row-count
	{mso-style-name:ui-ncbigrid-select-row-count;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenulia, li.ui-ncbibasicmenulia, div.ui-ncbibasicmenulia
	{mso-style-name:ui-ncbibasicmenu>li>a;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbimenu-item-leaf, li.ui-ncbimenu-item-leaf, div.ui-ncbimenu-item-leaf
	{mso-style-name:ui-ncbimenu-item-leaf;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.brieflinkpop, li.brieflinkpop, div.brieflinkpop
	{mso-style-name:brieflinkpop;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.star, li.star, div.star
	{mso-style-name:star;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbisetswitch, li.jig-ncbisetswitch, div.jig-ncbisetswitch
	{mso-style-name:jig-ncbisetswitch;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-button, li.ui-ncbisetswitch-button, div.ui-ncbisetswitch-button
	{mso-style-name:ui-ncbisetswitch-button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-options, li.ui-ncbisetswitch-options, div.ui-ncbisetswitch-options
	{mso-style-name:ui-ncbisetswitch-options;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.boxed-text-box, li.boxed-text-box, div.boxed-text-box
	{mso-style-name:boxed-text-box;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-from, li.cell-from, div.cell-from
	{mso-style-name:cell-from;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-citation, li.cell-citation, div.cell-citation
	{mso-style-name:cell-citation;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup, li.figpopup, div.figpopup
	{mso-style-name:figpopup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.button, li.button, div.button
	{mso-style-name:button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.retraction, li.retraction, div.retraction
	{mso-style-name:retraction;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverarrow, li.mathjaxhoverarrow, div.mathjaxhoverarrow
	{mso-style-name:mathjax_hover_arrow;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pbody, li.pbody, div.pbody
	{mso-style-name:pbody;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box, li.page-box, div.page-box
	{mso-style-name:page-box;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box-wide, li.page-box-wide, div.page-box-wide
	{mso-style-name:page-box-wide;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nomaxwidth, li.nomaxwidth, div.nomaxwidth
	{mso-style-name:no_max_width;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.f, li.f, div.f
	{mso-style-name:f;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.l, li.l, div.l
	{mso-style-name:l;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header-icon, li.ui-accordion-header-icon, div.ui-accordion-header-icon
	{mso-style-name:ui-accordion-header-icon;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-optgroup, li.ui-selectmenu-optgroup, div.ui-selectmenu-optgroup
	{mso-style-name:ui-selectmenu-optgroup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-anchor, li.ui-tabs-anchor, div.ui-tabs-anchor
	{mso-style-name:ui-tabs-anchor;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-submit, li.ui-ncbibutton-submit, div.ui-ncbibutton-submit
	{mso-style-name:ui-ncbibutton-submit;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-cancel, li.ui-ncbibutton-cancel, div.ui-ncbibutton-cancel
	{mso-style-name:ui-ncbibutton-cancel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ltd-hover, li.ltd-hover, div.ltd-hover
	{mso-style-name:ltd-hover;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.warn, li.warn, div.warn
	{mso-style-name:warn;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notice, li.notice, div.notice
	{mso-style-name:notice;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content, li.content, div.content
	{mso-style-name:content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.onelinesource, li.onelinesource, div.onelinesource
	{mso-style-name:one_line_source;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tertiary, li.tertiary, div.tertiary
	{mso-style-name:tertiary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverframe, li.mathjaxhoverframe, div.mathjaxhoverframe
	{mso-style-name:mathjax_hover_frame;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.other-issues
	{mso-style-name:other-issues;}
span.underline
	{mso-style-name:underline;}
span.double-underline
	{mso-style-name:double-underline;}
span.bold-double-underline
	{mso-style-name:bold-double-underline;}
span.ui-icon1
	{mso-style-name:ui-icon1;}
span.ui-selectmenu-text
	{mso-style-name:ui-selectmenu-text;}
span.pagelink
	{mso-style-name:page_link;}
span.ui-icon-plus-minus-big
	{mso-style-name:ui-icon-plus-minus-big;}
span.ui-icon-plus-minus-big-open
	{mso-style-name:ui-icon-plus-minus-big-open;}
span.collapsabletbodyicon
	{mso-style-name:collapsabletbodyicon;}
p.ui-accordion-header1, li.ui-accordion-header1, div.ui-accordion-header1
	{mso-style-name:ui-accordion-header1;
	margin-top:1.5pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons1, li.ui-accordion-icons1, div.ui-accordion-icons1
	{mso-style-name:ui-accordion-icons1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons2, li.ui-accordion-icons2, div.ui-accordion-icons2
	{mso-style-name:ui-accordion-icons2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header-icon1, li.ui-accordion-header-icon1, div.ui-accordion-header-icon1
	{mso-style-name:ui-accordion-header-icon1;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-content1, li.ui-accordion-content1, div.ui-accordion-content1
	{mso-style-name:ui-accordion-content1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text1, li.ui-button-text1, div.ui-button-text1
	{mso-style-name:ui-button-text1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text2, li.ui-button-text2, div.ui-button-text2
	{mso-style-name:ui-button-text2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text3, li.ui-button-text3, div.ui-button-text3
	{mso-style-name:ui-button-text3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon2, li.ui-icon2, div.ui-icon2
	{mso-style-name:ui-icon2;
	margin-top:0in;
	margin-right:0in;
	margin-left:-6.0pt;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button1, li.ui-button1, div.ui-button1
	{mso-style-name:ui-button1;
	margin-right:-.05in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header1, li.ui-datepicker-header1, div.ui-datepicker-header1
	{mso-style-name:ui-datepicker-header1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-next1, li.ui-datepicker-next1, div.ui-datepicker-next1
	{mso-style-name:ui-datepicker-next1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-prev1, li.ui-datepicker-prev1, div.ui-datepicker-prev1
	{mso-style-name:ui-datepicker-prev1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-title1, li.ui-datepicker-title1, div.ui-datepicker-title1
	{mso-style-name:ui-datepicker-title1;
	margin-top:0in;
	margin-right:27.6pt;
	margin-bottom:0in;
	margin-left:27.6pt;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:21.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane1, li.ui-datepicker-buttonpane1, div.ui-datepicker-buttonpane1
	{mso-style-name:ui-datepicker-buttonpane1;
	margin-top:8.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group1, li.ui-datepicker-group1, div.ui-datepicker-group1
	{mso-style-name:ui-datepicker-group1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group2, li.ui-datepicker-group2, div.ui-datepicker-group2
	{mso-style-name:ui-datepicker-group2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group3, li.ui-datepicker-group3, div.ui-datepicker-group3
	{mso-style-name:ui-datepicker-group3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header2, li.ui-datepicker-header2, div.ui-datepicker-header2
	{mso-style-name:ui-datepicker-header2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header3, li.ui-datepicker-header3, div.ui-datepicker-header3
	{mso-style-name:ui-datepicker-header3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane2, li.ui-datepicker-buttonpane2, div.ui-datepicker-buttonpane2
	{mso-style-name:ui-datepicker-buttonpane2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane3, li.ui-datepicker-buttonpane3, div.ui-datepicker-buttonpane3
	{mso-style-name:ui-datepicker-buttonpane3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header4, li.ui-datepicker-header4, div.ui-datepicker-header4
	{mso-style-name:ui-datepicker-header4;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header5, li.ui-datepicker-header5, div.ui-datepicker-header5
	{mso-style-name:ui-datepicker-header5;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-title1, li.ui-dialog-title1, div.ui-dialog-title1
	{mso-style-name:ui-dialog-title1;
	margin-top:1.2pt;
	margin-right:12.0pt;
	margin-bottom:2.4pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-buttonpane1, li.ui-dialog-buttonpane1, div.ui-dialog-buttonpane1
	{mso-style-name:ui-dialog-buttonpane1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-left:0in;
	background:whitesmoke;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-item1, li.ui-menu-item1, div.ui-menu-item1
	{mso-style-name:ui-menu-item1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-divider1, li.ui-menu-divider1, div.ui-menu-divider1
	{mso-style-name:ui-menu-divider1;
	margin-top:3.75pt;
	margin-right:0in;
	margin-bottom:3.75pt;
	margin-left:0in;
	line-height:0%;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-active1, li.ui-state-active1, div.ui-state-active1
	{mso-style-name:ui-state-active1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-focus1, li.ui-state-focus1, div.ui-state-focus1
	{mso-style-name:ui-state-focus1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-menu-item2, li.ui-menu-item2, div.ui-menu-item2
	{mso-style-name:ui-menu-item2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon3, li.ui-icon3, div.ui-icon3
	{mso-style-name:ui-icon3;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value1, li.ui-progressbar-value1, div.ui-progressbar-value1
	{mso-style-name:ui-progressbar-value1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-overlay1, li.ui-progressbar-overlay1, div.ui-progressbar-overlay1
	{mso-style-name:ui-progressbar-overlay1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value2, li.ui-progressbar-value2, div.ui-progressbar-value2
	{mso-style-name:ui-progressbar-value2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-handle1, li.ui-resizable-handle1, div.ui-resizable-handle1
	{mso-style-name:ui-resizable-handle1;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-resizable-handle2, li.ui-resizable-handle2, div.ui-resizable-handle2
	{mso-style-name:ui-resizable-handle2;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-menu1, li.ui-menu1, div.ui-menu1
	{mso-style-name:ui-menu1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-optgroup1, li.ui-selectmenu-optgroup1, div.ui-selectmenu-optgroup1
	{mso-style-name:ui-selectmenu-optgroup1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.ui-icon4
	{mso-style-name:ui-icon4;}
span.ui-selectmenu-text1
	{mso-style-name:ui-selectmenu-text1;}
p.ui-slider-handle1, li.ui-slider-handle1, div.ui-slider-handle1
	{mso-style-name:ui-slider-handle1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range1, li.ui-slider-range1, div.ui-slider-range1
	{mso-style-name:ui-slider-range1;
	margin-right:0in;
	margin-left:0in;
	font-size:8.5pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle2, li.ui-slider-handle2, div.ui-slider-handle2
	{mso-style-name:ui-slider-handle2;
	margin-right:0in;
	margin-left:-.1in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle3, li.ui-slider-handle3, div.ui-slider-handle3
	{mso-style-name:ui-slider-handle3;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range2, li.ui-slider-range2, div.ui-slider-range2
	{mso-style-name:ui-slider-range2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon5, li.ui-icon5, div.ui-icon5
	{mso-style-name:ui-icon5;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-anchor1, li.ui-tabs-anchor1, div.ui-tabs-anchor1
	{mso-style-name:ui-tabs-anchor1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tooltip1, li.ui-tooltip1, div.ui-tooltip1
	{mso-style-name:ui-tooltip1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget1, li.ui-widget1, div.ui-widget1
	{mso-style-name:ui-widget1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.ui-state-default1, li.ui-state-default1, div.ui-state-default1
	{mso-style-name:ui-state-default1;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-default2, li.ui-state-default2, div.ui-state-default2
	{mso-style-name:ui-state-default2;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-focus2, li.ui-state-focus2, div.ui-state-focus2
	{mso-style-name:ui-state-focus2;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover1, li.ui-state-hover1, div.ui-state-hover1
	{mso-style-name:ui-state-hover1;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-focus3, li.ui-state-focus3, div.ui-state-focus3
	{mso-style-name:ui-state-focus3;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover2, li.ui-state-hover2, div.ui-state-hover2
	{mso-style-name:ui-state-hover2;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active2, li.ui-state-active2, div.ui-state-active2
	{mso-style-name:ui-state-active2;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active3, li.ui-state-active3, div.ui-state-active3
	{mso-style-name:ui-state-active3;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-highlight1, li.ui-state-highlight1, div.ui-state-highlight1
	{mso-style-name:ui-state-highlight1;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-highlight2, li.ui-state-highlight2, div.ui-state-highlight2
	{mso-style-name:ui-state-highlight2;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-error1, li.ui-state-error1, div.ui-state-error1
	{mso-style-name:ui-state-error1;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error2, li.ui-state-error2, div.ui-state-error2
	{mso-style-name:ui-state-error2;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text1, li.ui-state-error-text1, div.ui-state-error-text1
	{mso-style-name:ui-state-error-text1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text2, li.ui-state-error-text2, div.ui-state-error-text2
	{mso-style-name:ui-state-error-text2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-priority-primary1, li.ui-priority-primary1, div.ui-priority-primary1
	{mso-style-name:ui-priority-primary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-primary2, li.ui-priority-primary2, div.ui-priority-primary2
	{mso-style-name:ui-priority-primary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-secondary1, li.ui-priority-secondary1, div.ui-priority-secondary1
	{mso-style-name:ui-priority-secondary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-priority-secondary2, li.ui-priority-secondary2, div.ui-priority-secondary2
	{mso-style-name:ui-priority-secondary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled1, li.ui-state-disabled1, div.ui-state-disabled1
	{mso-style-name:ui-state-disabled1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled2, li.ui-state-disabled2, div.ui-state-disabled2
	{mso-style-name:ui-state-disabled2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon6, li.ui-icon6, div.ui-icon6
	{mso-style-name:ui-icon6;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon7, li.ui-icon7, div.ui-icon7
	{mso-style-name:ui-icon7;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon8, li.ui-icon8, div.ui-icon8
	{mso-style-name:ui-icon8;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon9, li.ui-icon9, div.ui-icon9
	{mso-style-name:ui-icon9;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon10, li.ui-icon10, div.ui-icon10
	{mso-style-name:ui-icon10;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon11, li.ui-icon11, div.ui-icon11
	{mso-style-name:ui-icon11;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon12, li.ui-icon12, div.ui-icon12
	{mso-style-name:ui-icon12;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon13, li.ui-icon13, div.ui-icon13
	{mso-style-name:ui-icon13;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon14, li.ui-icon14, div.ui-icon14
	{mso-style-name:ui-icon14;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-nav1, li.ui-tabs-nav1, div.ui-tabs-nav1
	{mso-style-name:ui-tabs-nav1;
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tertiary1, li.tertiary1, div.tertiary1
	{mso-style-name:tertiary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#666666;}
p.tertiary2, li.tertiary2, div.tertiary2
	{mso-style-name:tertiary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#985735;}
p.ui-tabs-panel1, li.ui-tabs-panel1, div.ui-tabs-panel1
	{mso-style-name:ui-tabs-panel1;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-hide1, li.ui-tabs-hide1, div.ui-tabs-hide1
	{mso-style-name:ui-tabs-hide1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-dialog-titlebar1, li.ui-dialog-titlebar1, div.ui-dialog-titlebar1
	{mso-style-name:ui-dialog-titlebar1;
	margin-right:0in;
	margin-left:0in;
	background:#3E72A6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.ui-dialog-titlebar-close1, li.ui-dialog-titlebar-close1, div.ui-dialog-titlebar-close1
	{mso-style-name:ui-dialog-titlebar-close1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-content1, li.ui-dialog-content1, div.ui-dialog-content1
	{mso-style-name:ui-dialog-content1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-se1, li.ui-resizable-se1, div.ui-resizable-se1
	{mso-style-name:ui-resizable-se1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon15, li.ui-icon15, div.ui-icon15
	{mso-style-name:ui-icon15;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-hover3, li.ui-state-hover3, div.ui-state-hover3
	{mso-style-name:ui-state-hover3;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-ncbibutton-submit1, li.ui-ncbibutton-submit1, div.ui-ncbibutton-submit1
	{mso-style-name:ui-ncbibutton-submit1;
	margin-right:6.55pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-cancel1, li.ui-ncbibutton-cancel1, div.ui-ncbibutton-cancel1
	{mso-style-name:ui-ncbibutton-cancel1;
	margin-right:0in;
	margin-left:0in;
	line-height:22.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#2F4A8B;}
p.ui-button-text4, li.ui-button-text4, div.ui-button-text4
	{mso-style-name:ui-button-text4;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref-right1, li.ui-ncbiautocomplete-link-pref-right1, div.ui-ncbiautocomplete-link-pref-right1
	{mso-style-name:ui-ncbiautocomplete-link-pref-right1;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text5, li.ui-button-text5, div.ui-button-text5
	{mso-style-name:ui-button-text5;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text6, li.ui-button-text6, div.ui-button-text6
	{mso-style-name:ui-button-text6;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text7, li.ui-button-text7, div.ui-button-text7
	{mso-style-name:ui-button-text7;
	margin-right:0in;
	margin-left:0in;
	text-indent:595.95pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text8, li.ui-button-text8, div.ui-button-text8
	{mso-style-name:ui-button-text8;
	margin-right:0in;
	margin-left:0in;
	text-indent:595.95pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text9, li.ui-button-text9, div.ui-button-text9
	{mso-style-name:ui-button-text9;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text10, li.ui-button-text10, div.ui-button-text10
	{mso-style-name:ui-button-text10;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon16, li.ui-icon16, div.ui-icon16
	{mso-style-name:ui-icon16;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon17, li.ui-icon17, div.ui-icon17
	{mso-style-name:ui-icon17;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon18, li.ui-icon18, div.ui-icon18
	{mso-style-name:ui-icon18;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon19, li.ui-icon19, div.ui-icon19
	{mso-style-name:ui-icon19;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon20, li.ui-icon20, div.ui-icon20
	{mso-style-name:ui-icon20;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon21, li.ui-icon21, div.ui-icon21
	{mso-style-name:ui-icon21;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary1, li.ui-button-icon-primary1, div.ui-button-icon-primary1
	{mso-style-name:ui-button-icon-primary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary2, li.ui-button-icon-primary2, div.ui-button-icon-primary2
	{mso-style-name:ui-button-icon-primary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary3, li.ui-button-icon-primary3, div.ui-button-icon-primary3
	{mso-style-name:ui-button-icon-primary3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary1, li.ui-button-icon-secondary1, div.ui-button-icon-secondary1
	{mso-style-name:ui-button-icon-secondary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary2, li.ui-button-icon-secondary2, div.ui-button-icon-secondary2
	{mso-style-name:ui-button-icon-secondary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-pagecontrol1, li.ui-ncbigrid-paged-pagecontrol1, div.ui-ncbigrid-paged-pagecontrol1
	{mso-style-name:ui-ncbigrid-paged-pagecontrol1;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.prev1, li.prev1, div.prev1
	{mso-style-name:prev1;
	margin-right:.1in;
	margin-left:2.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.next1, li.next1, div.next1
	{mso-style-name:next1;
	margin-right:2.4pt;
	margin-left:.1in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-row-count1, li.ui-ncbigrid-select-row-count1, div.ui-ncbigrid-select-row-count1
	{mso-style-name:ui-ncbigrid-select-row-count1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.pagelink1
	{mso-style-name:page_link1;
	color:#CCCCCC;}
span.collapsabletbodyicon1
	{mso-style-name:collapsabletbodyicon1;}
span.ui-icon-plus-minus-big1
	{mso-style-name:ui-icon-plus-minus-big1;}
span.ui-icon-plus-minus-big-open1
	{mso-style-name:ui-icon-plus-minus-big-open1;}
p.ui-ncbigrid-outer-div1, li.ui-ncbigrid-outer-div1, div.ui-ncbigrid-outer-div1
	{mso-style-name:ui-ncbigrid-outer-div1;
	margin:0in;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbimenu-item-leaf1, li.ui-ncbimenu-item-leaf1, div.ui-ncbimenu-item-leaf1
	{mso-style-name:ui-ncbimenu-item-leaf1;
	margin-top:0in;
	margin-right:9.0pt;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.brieflinkpop1, li.brieflinkpop1, div.brieflinkpop1
	{mso-style-name:brieflinkpop1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.ui-icon-plus-minus-big2
	{mso-style-name:ui-icon-plus-minus-big2;}
span.ui-icon-plus-minus-big-open2
	{mso-style-name:ui-icon-plus-minus-big-open2;}
span.ui-icon22
	{mso-style-name:ui-icon22;}
span.ui-icon23
	{mso-style-name:ui-icon23;}
p.star1, li.star1, div.star1
	{mso-style-name:star1;
	margin-right:7.4pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbisetswitch1, li.jig-ncbisetswitch1, div.jig-ncbisetswitch1
	{mso-style-name:jig-ncbisetswitch1;
	margin-right:0in;
	margin-left:0in;
	line-height:14.75pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#333333;}
p.ui-ncbisetswitch-button1, li.ui-ncbisetswitch-button1, div.ui-ncbisetswitch-button1
	{mso-style-name:ui-ncbisetswitch-button1;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon24, li.ui-icon24, div.ui-icon24
	{mso-style-name:ui-icon24;
	margin:5.55pt;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ltd-hover1, li.ltd-hover1, div.ltd-hover1
	{mso-style-name:ltd-hover1;
	margin-right:0in;
	margin-left:0in;
	background:#E8E8E8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon25, li.ui-icon25, div.ui-icon25
	{mso-style-name:ui-icon25;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-options1, li.ui-ncbisetswitch-options1, div.ui-ncbisetswitch-options1
	{mso-style-name:ui-ncbisetswitch-options1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pbody1, li.pbody1, div.pbody1
	{mso-style-name:pbody1;
	margin-top:0in;
	margin-right:16.6pt;
	margin-bottom:0in;
	margin-left:16.6pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box1, li.page-box1, div.page-box1
	{mso-style-name:page-box1;
	margin-top:16.6pt;
	margin-right:0in;
	margin-bottom:16.6pt;
	margin-left:0in;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box-wide1, li.page-box-wide1, div.page-box-wide1
	{mso-style-name:page-box-wide1;
	margin-top:16.6pt;
	margin-right:0in;
	margin-bottom:16.6pt;
	margin-left:0in;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nomaxwidth1, li.nomaxwidth1, div.nomaxwidth1
	{mso-style-name:no_max_width1;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content1, li.content1, div.content1
	{mso-style-name:content1;
	margin:16.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.boxed-text-box1, li.boxed-text-box1, div.boxed-text-box1
	{mso-style-name:boxed-text-box1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.f1, li.f1, div.f1
	{mso-style-name:f1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.l1, li.l1, div.l1
	{mso-style-name:l1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-from1, li.cell-from1, div.cell-from1
	{mso-style-name:cell-from1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.cell-citation1, li.cell-citation1, div.cell-citation1
	{mso-style-name:cell-citation1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup1, li.figpopup1, div.figpopup1
	{mso-style-name:figpopup1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.button1, li.button1, div.button1
	{mso-style-name:button1;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#336699;}
p.retraction1, li.retraction1, div.retraction1
	{mso-style-name:retraction1;
	margin-right:0in;
	margin-left:0in;
	background:red;
	font-size:12.0pt;
	font-family:"Helvetica","sans-serif";
	color:#F0F0F0;}
p.warn1, li.warn1, div.warn1
	{mso-style-name:warn1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notice1, li.notice1, div.notice1
	{mso-style-name:notice1;
	margin-right:0in;
	margin-left:0in;
	font-size:16.5pt;
	font-family:"Times New Roman","serif";}
p.arrowtab1, li.arrowtab1, div.arrowtab1
	{mso-style-name:arrowtab1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.thistab1, li.thistab1, div.thistab1
	{mso-style-name:thistab1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F6F6F6;
	border:none;
	padding:0in;
	font-size:9.5pt;
	font-family:"Arial","sans-serif";
	font-weight:bold;}
p.onelinesource1, li.onelinesource1, div.onelinesource1
	{mso-style-name:one_line_source1;
	margin-right:0in;
	margin-left:0in;
	background:#E0E0E0;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverarrow1, li.mathjaxhoverarrow1, div.mathjaxhoverarrow1
	{mso-style-name:mathjax_hover_arrow1;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:7.0pt;
	font-family:"Courier New";
	color:#F0F0F0;}
p.mathjaxmenuarrow1, li.mathjaxmenuarrow1, div.mathjaxmenuarrow1
	{mso-style-name:mathjax_menuarrow1;
	margin-right:0in;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Arial Unicode MS","sans-serif";
	color:white;}
span.cit
	{mso-style-name:cit;}
span.fm-vol-iss-date
	{mso-style-name:fm-vol-iss-date;}
span.doi1
	{mso-style-name:doi1;}
span.fm-citation-ids-label
	{mso-style-name:fm-citation-ids-label;}
span.fm-role
	{mso-style-name:fm-role;}
p.p, li.p, div.p
	{mso-style-name:p;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.figpopup-sensitive-area1
	{mso-style-name:figpopup-sensitive-area1;
	text-decoration:none none;}
p.fn, li.fn, div.fn
	{mso-style-name:fn;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.element-citation
	{mso-style-name:element-citation;}
span.ref-journal
	{mso-style-name:ref-journal;}
span.ref-vol
	{mso-style-name:ref-vol;}
span.nowrap
	{mso-style-name:nowrap;}
span.acknowledgment-journal-title
	{mso-style-name:acknowledgment-journal-title;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma","sans-serif";}
.MsoChpDefault
	{font-family:"Calibri","sans-serif";}
.MsoPapDefault
	{margin-bottom:10.0pt;
	line-height:115%;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple>

<div class=WordSection1>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PLoS
One. 2011; 6(4): e18424. </span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Published
online 2011 Apr 6. doi:&nbsp; <a
href="http://dx.doi.org/10.1371%2Fjournal.pone.0018424" target="pmc_ext">10.1371/journal.pone.0018424</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PMCID:
PMC3071831</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:24.0pt;font-family:"Times New Roman","serif"'>Targeted
Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth
Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Subbiah%20V%5Bauth%5D">Vivek
Subbiah</a>,<sup>1,2,*</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Naing%20A%5Bauth%5D">Aung Naing</a>,<sup>2</sup>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Brown%20RE%5Bauth%5D">Robert
E. Brown</a>,<sup>3</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Chen%20H%5Bauth%5D">Helen Chen</a>,<sup>4</sup>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Doyle%20L%5Bauth%5D">Laurence
Doyle</a>,<sup>4</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=LoRusso%20P%5Bauth%5D">Patricia
LoRusso</a>,<sup>5</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Benjamin%20R%5Bauth%5D">Robert
Benjamin</a>,<sup>6</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Anderson%20P%5Bauth%5D">Pete
Anderson</a>,<sup>1</sup> and <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kurzrock%20R%5Bauth%5D">Razelle
Kurzrock</a><sup>2</sup></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Benjamin
Edward Rich, Editor</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>1</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Department of Pediatrics, The
University of Texas MD Anderson Cancer Center, Houston, Texas</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>2</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Department of Investigational Cancer
Therapeutics (Phase I Clinical Trials Program), The University of Texas MD
Anderson Cancer Center, Houston, Texas</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>3</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Department of Pathology and Laboratory
Medicine, UT Health, University of TexasHouston Medical School, Houston, Texas</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>4</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Cancer Therapy Evaluation Program,
National Cancer Institute, Bethesda, Maryland</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>5</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Wayne State UniversityBarbara Ann
Karmanos Cancer Institute, Detroit, Michigan</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>6</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Division of Cancer Medicine, Department
of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center,
Houston, Texas</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Dana-Farber Cancer Institute, United States of America</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>* E-mail: <a href="mailto:dev@null">gro.nosrednadm@haibbusv</a></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";display:none'>Conceived and
designed the experiments: VS AN REB RK. Performed the experiments: VS AN REB
RK. Analyzed the data: VS AN REB HC PA RK. Contributed
reagents/materials/analysis tools: VS AN REB HC LD PL RB PA RK. Wrote the
paper: VS REB RK.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/">Author information
&#9658;</a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/">Article
notes &#9658;</a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/">Copyright
and License information &#9658;</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Received 2010 Nov 4; Accepted 2011 Mar 5.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a>
This is an open-access article, free of all copyright, and may be freely
reproduced, distributed, transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made available under the Creative
Commons CC0 public domain dedication.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>This
article has been <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/citedby/">cited by</a>
other articles in PMC.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Abstract</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Background</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:lime'>Insulin-like
growth factor 1 receptor (IGF1R) targeted therapies have resulted in responses
in a small number of patients with advanced metastatic Ewing's sarcoma.</span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'> <span
style='background:yellow'>We performed morphoproteomic profiling to better
understand response/resistance mechanisms of Ewing's sarcoma to IGF1R
inhibitor-based therapy.</span></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Methodology/Principal
Findings</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>This pilot
study assessed two patients with advanced Ewing's sarcoma treated with IGF1R
antibody alone followed by combined IGF1R inhibitor plus mammalian target of
rapamycin (mTOR) inhibitor treatment once resistance to single-agent IGF1R
inhibitor developed.</span><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'> <span style='background:yellow'>Immunohistochemical
probes were applied to detect p-mTOR (Ser2448), p-Akt (Ser473), p-ERK1/2
(Thr202/Tyr204), nestin, and p-STAT3 (Tyr 705) in the original and recurrent
tumor.</span> <span style='background:yellow'>The initial remarkable
radiographic responses to IGF1R-antibody therapy was followed by resistance and
then response to combined IGF1R plus mTOR inhibitor therapy in both patients,
and then resistance to the combination regimen in one patient.</span> <span
style='background:yellow'>In patient 1, upregulation of p-Akt and p-mTOR in the
tumor that relapsed after initial response to IGF1R antibody might explain the
resistance that developed, and the subsequent response to combined IGF1R plus
mTOR inhibitor therapy.</span> <span style='background:yellow'>In patient 2,
upregulation of mTOR was seen in the primary tumor, perhaps explaining the
initial response to the IGF1R and mTOR inhibitor combination, while the
resistant tumor that emerged showed activation of the ERK pathway as well.</span></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Conclusion/Significance</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>Morphoproteomic
analysis revealed that the mTOR pathway was activated in these two patients
with advanced Ewing's sarcoma who showed response to combined IGF1R and mTOR
inhibition, and the ERK pathway in the patient in whom resistance to this
combination emerged.</span><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'> Our pilot results suggests that morphoproteomic
assessment of signaling pathway activation in Ewing's sarcoma merits further
investigation as a guide to understanding response and resistance signatures.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Introduction</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Ewing's sarcoma is the second
most common malignant bone tumor in children, adolescents and young adults.
Despite using a multimodal approach combining surgery, chemotherapy, and
radiation, a therapeutic plateau has been attained with no change in overall
survival <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Balamuth1">[1]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Smith1">[2]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Subbiah1">[3]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Subbiah2">[4]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Ludwig1">[5]</a>.
Attempts to improve clinical outcome through collaborative trials beginning in
the early 1970s sought to optimize care through ever more
mechanistically-diverse chemotherapies. Strategies included increasing duration
of treatment or dosage per cycle, decreasing treatment interval (i.e., interval
dose compression), or using high-dose myeloablative chemotherapy followed by
peripheral blood stem cell transplant <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Subbiah1">[3]</a>.
However, survival remains poor for patients with metastatic disease. For
metastatic Ewing's sarcoma at diagnosis, the risk of refractory or recurrent
disease approaches 80% after initial therapy and the outcome of recurrent
disease is poor with event-free survival less than 20% <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Subbiah1">[3]</a>.
Treatment options for patients with refractory or recurrent Ewing's sarcoma are
limited.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Early phase clinical trials
frequently combine targeted agents to optimize benefit. Two challenges at the
outset are 1) deciding which agents to combine given the heterogeneity of
tumors and their various underlying resistance pathways and feedback loops, and
2) how to translate findings from the bench to the bedside or directly from the
bedside <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Rodon1">[6]</a>.
Morphoproteomics (morphology+proteomics) involves immunohistochemical
assessment of the activation of signaling pathways in cancer cells, and
predicting susceptibility to small-molecule inhibitors, specific
chemotherapeutic agents, and possibly, differentiating agents <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Brown1">[7]</a>.
In some cases, drugs that fail early in the disease trajectory can produce
renewed tumor regression later, particularly with rational addition of another
drug <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Naing1">[8]</a>.
Morphoproteomics can potentially identify targeted combinations of drugs
appropriate for prospective testing <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Brown2">[9]</a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Insulin-like growth factor 1
receptor (IGF1R)-targeted therapies have shown early promise <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Rodon2">[10]</a>,
with responses in a small number of patients with Ewing's sarcoma <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Subbiah2">[4]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Tolcher1">[11]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Kurzrock1">[12]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Olmos1">[13]</a>.
Currently available IGF1R antibodies recognize different epitopes of the
receptor and, therefore, may exert different biological/clinical responses <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Maki1">[14]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Olmos2">[15]</a>.
Even so, phase I studies with different IGF1R antibodies demonstrated
remarkable responses in a subset of Ewing's sarcoma patients <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Tolcher1">[11]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Kurzrock1">[12]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Olmos1">[13]</a>.
While response rates in Phase II studies have not yet been reported, it is
clear that while some responses have been dramatic, they occurred in only a
minority of patients. The mechanisms underlying primary and secondary response
and resistance are unknown.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Herein, we report our experience
with two index cases of Ewing's sarcoma, with an initial positive response to
an IGF1R inhibitor followed by resistance. <span style='background:yellow'>Both
patients subsequently responded to a combination of an IGF1R inhibitor and a
mammalian target of rapamycin (mTOR) inhibitor.</span> We performed
morphoproteomic profiling to elucidate the functional signaling pathways in
both patients.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Methods</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Patient
Selection, Treatment and Clinical Assessments</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>We reviewed the medical records
of two patients with Ewing's sarcoma who were seen in the Phase I Clinical
Trials Program at The University of Texas MD Anderson Cancer Center and
initially treated with an IGF1R inhibitor alone, then subsequently with an
IGF1R and mTOR inhibitor combination. The patients in this manuscript have
given written informed consent (as outlined in the PLoS consent form) to
publication of their clinical details. Treatment and consent on investigational
trials, and data collection and morphoproteomic analysis were performed in
accordance with the guidelines of the University of Texas MD Anderson Cancer
Center Institutional Review Board (IRB).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The patients in the manuscript
were derived from two different Phase I studies and a Phase II study using
different IGF1R inhibitors and all the studies have been registered in <a
href="http://www.clinicaltrials.gov/" target="pmc_ext">www.clinicaltrials.gov</a>.
The scope of the studies, current status and clinical trial registration
identifiers are as follows:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>1. A Multiple Ascending Dose
Study of R1507 in Patients with Advanced Solid Tumors (now closed and not
actively recruiting patients) NCT00400361 (Phase I),</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>2. A Study to Determine the
Activity of SCH 717454 in Subjects with Relapsed Osteosarcoma or Ewing's
Sarcoma (Study P04720AM3) (now closed and not actively recruiting patients)
NCT00617890 (Phase II),</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>3. IMC-A12 in Combination with
Temsirolimus (CCI-779) in Patients With Advanced Cancers (Study is closed to
Ewing's Sarcoma cohort) NCT00678769 (Phase I).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>After initiation of an
investigational therapy, patients were evaluated clinically at 3- to 4-week
intervals. At each visit, a history was taken and physical examination
performed along with comprehensive metabolic and hematologic panels. Patients
were assessed for the onset of new symptoms and compliance with the
investigational therapy. Tumor response was determined using Response
Evaluation Criteria in Solid Tumors (RECIST) version 3.1 by positron emission
tomography/computed tomography (PET/CT) scans or CT scans obtained about every
six to eight weeks. Sections of original and recurrent tumor were available for
analysis. The morphoproteomic analysis reported in this manuscript was not a
part of the original Phase 1 trial protocols, and were carried out as a
separate subsequent analysis. Patient consent and MD Anderson IRB approval were
obtained for morphoproteomic analysis as outlined above.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Immunohistochemical
and Morphoproteomic Analysis</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Immunohistochemical (IHC) probes
were used to detect the following phosphorylated (p) antigens as published
previously<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Zenali1">[16]</a>:
p-mTOR (Ser 2448); p-Akt (Ser 473);and p-extracellular signal-regulated kinase
(ERK) 1/2 (Thr 202/Tyr204) [Cell Signaling Technology, Beverly, MA]; and
p-signal transducer and activator of transcription (STAT)3 (Tyr 705) [Santa
Cruz Biotechnology, Santa Cruz, CA]. In addition, IHC probes in specimens from
the two patients were applied to detect the expressions of CD99
(DakoCytomation, Carpinteria, CA) and nestin (abcam, Cambridge, MA). <span
style='background:yellow'>Chromogenic signals were evaluated by brightfield
microscopy and semi-quantified with regard to percentage of cells stained
(0100%) and the staining intensity (0: non-staining, 1+: weak staining, 2 +:
moderate staining, and 3 +: strong staining).</span> Subcellular
compartmentalizations were assessed as plasmalemmal, cytoplasmic, and/or
nuclear. Concurrently run positive and negative IHC controls reacted
appropriately. The methods have been published previously <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Brown1">[7]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Brown2">[9]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Zenali1">[16]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Shen1">[17]</a>
and were performed in a laboratory that is certified under the Clinical
Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform
high-complexity clinical testing.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Results</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Patient outcomes with
chemotherapy and targeted therapy are summarized below.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Patient 1 </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>A twenty-four year old Caucasian
woman presented with a three-year history of back pain and left lower extremity
pain. Magnetic resonance imaging (MRI) revealed a sacral mass, which was
determined to be Ewing's sarcoma following pathological assessment at MD
Anderson. The tumor cells were positive for CD99 and negative for chromogranin
A, keratin and desmin. She underwent six cycles of intravenous chemotherapy
through central line with vincristine (2 mg intravenous [IV]on day 1),
adriamycin (37.5 mg/m2/day IV for 2 days), and ifosfamide (2500 mg/m2 IV for 4
days) with MESNA uroprotection, followed by resection of the tumor, confirmed
as being Ewing's sarcoma. Fluorescent in situ hybridrization showed a positive
result for a clone with an <i>EWSR1</i> gene rearrangement. The patient
received postoperative radiation therapy, followed by six cycles of adjuvant
chemotherapy with irinotecan. After six months of follow-up, lung metastases
were discovered. She was started on etoposide and after five months, her tumors
progressed. Liposomal doxorubicin (Doxil) was initiated, but stopped after
tumor progression. The patient then underwent thoracotomy for removal of tumor,
followed by erlotinib, followed by another lung resection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>She was then referred to the
Phase I clinic at MD Anderson Cancer Center. A CT scan showed enlargement of
numerous pulmonary metastatic lesions, the largest measuring 5.9 cm5.1 cm. She
was treated on three sequential Phase I trials, with continued disease
progression. In December 2006, the patient was started on a Phase I study of
R1507 (Roche, Nutley NJ), a fully human IgG1 type monoclonal antibody against
IGF1R. Within six weeks, she had a dramatic response, with near complete tumor
regression (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g001/"
target=figure>Figure 1</a>, previously described in <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Kurzrock1">[12]</a>).
No toxicity was noted. After 20 months of continued treatment a small focus of
growing residual disease was found followed by surgical resection. Therapy
continued for another 15 months, followed by progressed disease in the
patient's lungs. She was started on another study using a different anti-IGF1R
antibody (IMC-A12; Imclone, San Diego CA) <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Rowinsky1">[18]</a>
in combination with the mTOR inhibitor temsirolimus (NCT00678769). She
tolerated this combination without any major side effects except a decrease in
platelet counts. After 14 months of treatment, both PET/CT and chest CT scans
show no disease (complete response) (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g002/"
target=figure>Figure 2</a>) and she continues on treatment.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g001/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=41 id="Picture 8"
src="PMC3071831%20table%201_files/image001.gif" alt="Figure 1"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g001/"
target=figure>Figure 1</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Imaging
Responses in Ewing's sarcoma patient 1.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g002/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=35 id="Picture 7"
src="PMC3071831%20table%201_files/image002.gif" alt="Figure 2"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g002/"
target=figure>Figure 2</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Imaging
Responses in Ewing's sarcoma patient 1.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Patient 2 </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>A twenty-one year old Caucasian
man presented with back pain radiating to the left leg in December 2006. An MRI
revealed a large left iliac mass extending into the sacroiliac joint. Biopsy
showed Ewing's sarcoma with a t(11;22) translocation. On presentation he had a
large left iliac primary lesion and bilateral pulmonary nodules and no evidence
of bone marrow disease. He was enrolled on the Children's Oncology Group Study
AEWS0031 (NCT00006734) and received standard q 3 week regimen consisting of vincristine
(2 mg/m2 IV push, on day 1. maximum dose 2 mg.), doxorubicin(75 mg/m2/course
continuous IV infusion over 48 hours, beginning day 1), cyclophosphamide (1200
mg/m2 IV infusion over 1 hour with MESNA uroprotection, on day 1), alternating
with ifosfamide (1800 mg/m2/day IV infusion over 1 hour, Days 15 of each
cycle. (9,000 mg/m2 max total dose) and etoposide (100 mg/m2/day IV infusion
over 1 to 2 hours, days 15 of each cycle (500 mg/m2 total dose). His pain
improved after one treatment and he had an excellent response. He then received
55.8 Gy radiation in 31 fractions to the pelvis for local control of the
unresectable disease, as well as whole lung radiation therapy for his pulmonary
nodules at the end of chemotherapy. He completed therapy with no evidence of
disease. Eight months later he developed recurrent pulmonary nodules. A PET/CT
scan showed activity only in lungs. He received topotecan and cyclophosphamide,
and although his tumors responded initially, they eventually progressed. The
patient then received temozolomide and irinotecan, without response, followed
by enrollment on an IGF1R inhibitor study using SCH 717454 (Schering,
Kenilworth NJ), an IGF1R antibody (19D12) <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Subbiah2">[4]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Wang1">[19]</a>.
He had near complete response (18 of 19 nodules improving or disappeared)
following 7 cycles. However, after 4 months, a solitary left lung nodule began
to grow, and he was taken off study for progressive disease by RECIST. A
thoracoscopic biopsy was done and confirmed Ewing's sarcoma. Subsequently, he
was started on etoposide, but disease continued to progress. He then presented
to the MD Anderson Phase I clinic and was enrolled on the protocol of IMC-A12,
IGF1R antibody in combination with Temsirolimus, mTOR inhibitor (NCT00678769).
Three out of four nodules showed a near complete response and one nodule
remained stable. However, after four months, one nodule began to grow, and he
was removed from study (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g003/"
target=figure>Figure 3</a>). The non-responding tumor was biopsied, and Ewing's
sarcoma was confirmed. Subsequently, the patient was treated with high-dose
ifosfamide and also received proton radiation therapy to the lung nodule.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g003/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=24 id="Picture 6"
src="PMC3071831%20table%201_files/image003.gif" alt="Figure 3"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g003/"
target=figure>Figure 3</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Imaging
Responses in Ewing's sarcoma patient 2.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Morphoproteomics
/Correlative Studies</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>The
pre-treatment similarities and differences between patient 1 and 2 are shown in
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/table/pone-0018424-t001/"
target=true>Table 1</a>.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/table/pone-0018424-t001/"
target=table><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=204 height=128 id="Picture 5"
src="PMC3071831%20table%201_files/image004.png" alt="Table 1"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/table/pone-0018424-t001/"
target=table>Table 1</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Targeted
Morphoproteomic Profiling of Ewing Sarcoma Patients Treated with Insulin-like
Growth Factor-1 Receptor (IGF-1R) Inhibitor: Pretreatment Specimens.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Patient 1 </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>A limited number of sections of
metastatic tumor from the following time points were available 1) before IGF1R
antibody therapy; and 2) from the resistant recurrence that emerged during
IGF1R antibody therapy (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g004/"
target=figure>Figure 4</a>). <span style='background:yellow'>Constitutive mTOR
pathway activation was noted in the pre-anti-IGF1R specimen (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g004/"
target=figure>Figure 4</a>) and reflected p-mTOR (Ser2448) expression in both
cytoplasmic plasmalemmal and nuclear compartments.</span> Similar findings have
been reported in the Ewing's family of tumors <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Zenali1">[16]</a>.
<span style='background:yellow'>There was also cytoplasmic plasmalemmal
expression of p-Akt (Ser473), but with almost no nuclear expression, which was
more consistent with P13K/Akt/mTORC1 signaling pathway activity.</span> <span
style='background:yellow'>In contrast, there was apparent upregulation of these
analytes in the specimen from the IGF1R-resistant tumor that emerged during
IGF1R antibody therapy, with predominant nuclear expression of both p-mTOR
(Ser2448) and p-Akt (Ser473), consistent with mTORC2 pathway activation <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Shen1">[17]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Rosner1">[20]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Sarbassov1">[21]</a>.</span>
<span style='background:yellow'>In both biopsies, only endothelial cells were
immunopositive for nestin, a neural precursor/differentiation marker, whereas
the tumor cells were immunonegative.</span> <span style='background:yellow'>Notably,
p-STAT3(Tyr705) was detected in a very minor component of the tumoral nuclei in
the initial biopsy and was variably expressed in the post-anti- IGF1R treatment
biopsy, ranging up to approximately one-half of the tumor cells in one
microanatomical region.</span></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g004/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=133 id="Picture 4"
src="PMC3071831%20table%201_files/image005.gif" alt="Figure 4"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g004/"
target=figure>Figure 4</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Schematic
clinical history and immunohistochemistry of patient 1.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Patient 2 </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Sections of tumor before IGF1R
antibody therapy and after IGF1R antibody combined with mTOR inhibitor therapy
were available for analysis (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g005/"
target=figure>Figure 5</a>). A greater number of sections were available than
for patient 1, permitting more extensive pathway evaluation (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g005/"
target=figure>Figure 5</a>).</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g005/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=147 id="Picture 3"
src="PMC3071831%20table%201_files/image006.gif" alt="Figure 5"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g005/"
target=figure>Figure 5</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Schematic
clinical history and immunohistochemistry of patient 2.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>There was constitutive activation
of mTOR in the patient's original and recurrent tumor, evidenced by
phosphorylation (p) of mTOR in a putative site of activation, Ser2448, with a
predominantly nuclear distribution most likely indicating an mTORC2 complex
(rictor + p-mTOR), <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Rosner1">[20]</a>
and correlative activation of Akt on Ser473 consistent with the presence of
both mTORC2 and dominant expression of p-Akt (Ser473) in tumoral nuclei <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Shen1">[17]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Rosner1">[20]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Sarbassov1">[21]</a>. <span style='background:yellow'>
Constitutive activation of the Ras/Raf /ERK pathway is noted in both specimens
by p-ERK 1/2 (Thr202/Tyr204) expression, showing nuclear translocation <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Brown2">[9]</a>.</span>
The expression appeared generalized and uniform in recurrent tumor and, to a
lesser degree, in the original (primary) tumor. <span style='background:yellow'>The
signal transducer and activator of transcription (STAT)3 pathway was
constitutively activated in both the primary and recurrent tumor, as evidenced
by expression with nuclear translocation of p-STAT3 (Tyr 705) in the vast
majority of tumor cells.</span> <span style='background:yellow'>The neural and
endothelial precursor marker, nestin, was weakly expressed in the original
(primary) tumor (01+).</span> <span style='background:yellow'>However, in the
recurrent tumor, nestin was expressed in approximately 25% to 50% of tumor
cells (up to 3+ cytoplasmic plasmalemmal expression) (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g005/"
target=figure>Figures 5</a> and <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g006/"
target=figure>&#8203;6</a>).</span>
Neural differentiation markers to CD56 and synaptophysin were expressed in
recurrent tumor in the plasmalemmal and cytoplasmic compartments (not shown).</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g006/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=172 id="Picture 2"
src="PMC3071831%20table%201_files/image007.gif" alt="Figure 6"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g006/"
target=figure>Figure 6</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>High
magnification immunohistochemistry showing nuclear versus cytoplasmic staining.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Discussion</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>There is no effective therapy for
advanced Ewing's sarcoma and patients with advanced metastatic disease succumb
to their disease. Two patients with Ewing's sarcoma who responded, but then
progressed after IGF1R inhibitor therapy alone showed consistently high mTORC2
expression in their tumors. Both patients responded after treatment to combined
IGF1R and mTOR inhibition. The time interval between the first and the second
IGF1R based therapy was 1 month for patient 1 and 4 months for patient 2. One
patient had a continued response and has remained on IGF1R-based therapy for
more than 50 months, the last 14 months of which has been an IGF1R inhibitor
combined with an mTOR inhibitor. The patient's last imaging scans showed no
disease. Unfortunately, the second patient acquired resistance.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Preclinical studies have shown
that mTOR is a bypass pathway for IGF1R targeting. Similarly, combined
inhibition of IGF1R and mTOR may circumvent counterproductive rapamycin-induced
upregulation of Akt that can occur within 6 hours of treatment <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Subbiah1">[3]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Bertrand1">[22]</a>.
Several Phase I/II clinical trials are currently investigating this potential
synergy in advanced malignancies. (Clinicaltrials.gov identifiers: NCT00678769;
NCT00880282 and NCT01016015).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>In this
context, our finding of upregulated p-Akt (Ser473) and p-mTOR (Ser2448) in
patient 1's resistant tumor that emerged following IGF1R antibody therapy is
consistent with a resistance mechanism that could be related to upregulation of
TORC2.</span><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>
The patient was, however, treated successfully with termsirolimus, a TORC1
inhibitor. Although short-term inhibition of TORC1 drives TORC2 formation and
results in Akt activation, long-term TORC1 inhibition abrogates Akt expression
through activation of S6K by PKD1 and also blocks TORC2 assembly <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Shah1">[23]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Sarbassov2">[24]</a>.
Activated S6K can down-modulate Akt by acting against insulin receptor
substrate 1 proteins and P13K <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Shah1">[23]</a>.
Although these pathways have often been depicted as linear, clearly there is a
complex interplay among signaling elements (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g007/"
target=figure>Figure 7</a>). EWS-FLI1 fusion protein, the hallmark of Ewing's
sarcoma, downregulates insulin-like growth factor binding protein 3, IGFBP3,
and upregulates IGF-1 expression resulting in enhanced IGF1R <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Prieur1">[25]</a>.
Therefore, treatment with an IGF1R inhibitor may counteract EWS-FLI1-mediated
upregulation of the insulin receptor (IR) /IGF1R machinery. Temsirolimus is a
rapalog and rapamycin has been shown to downregulate the EWS-FLI1 fusion
protein <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-MateoLozano1">[26]</a>
possibly also lessening IR/IGF1R signaling, and therefore providing an
additional pathway by which this molecule might be operative in this patient.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g007/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=75 id="Picture 1"
src="PMC3071831%20table%201_files/image008.gif" alt="Figure 7"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g007/"
target=figure>Figure 7</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Simplified
Insulin-like growth factor 1 receptor (IGF1R) and mTORC1 and mTORC2 signaling
in relation with EWS-FLI1.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>In patient 2,
constitutive activation of Akt and mTOR is similar to that in patient 1's
recurrent tumor, and is seen in baseline pre-treatment tumor and in tumor that
was resistant to IGF1R and mTOR combination treatment.</span><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'> These
observations suggest the possibility that the TORC2 pathway has a role in
primary and recurrent tumor <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Shen1">[17]</a>
(<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g005/"
target=figure>Figures 5</a>, <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g006/"
target=figure>&#8203;<span style='text-decoration:none'>,6,</span>6</a>, and <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g007/"
target=figure>&#8203;<span style='text-decoration:none'>and7).</span>7</a>).
After IGFR treatment alone, response was followed by resistance. Similarly, an
initial response was followed by re-emergence of resistance following treatment
with the IGFR-mTOR inhibitor combination. The mechanism of response to the IGFR
and mTOR combination may be similar to that in patient 1, that is, through Akt
and mTOR suppression that occurs with chronic temsirolimus exposure <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Shah1">[23]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Sarbassov2">[24]</a>.
The biologic activity of the mTOR inhibitor temsirolimus is further confirmed
by the upregulation of nestin seen in the patient's IGFR/mTOR resistant tumor,
since temsirolimus down-modulates EWS-FLI1, which would be expected to
upregulate nestin <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-MateoLozano1">[26]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-Galli1">[27]</a>
(<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g007/"
target=figure>Figure 7</a>). However, other pathways are operative in this
patient's tumor, including Ras/Raf /ERK and STAT3 (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/figure/pone-0018424-g005/"
target=figure>Figure 5</a>).The relative overexpression of CD99 in this patient
is consistent with activation of this pathway (not shown). In addition, p-Akt
and S6K are not downregulated by combined IGF1R and mTOR inhibition, perhaps
due to Ras/Raf/ERK activation. These signals might account for tumor resistance
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#pone.0018424-MateoLozano1">[26]</a>.
Of interest, in addition to nestin the patient's recurrent tumor showed a
propensity toward differentiation along neural lines, as demonstrated by
increased expression of other neural markers such as CD56 or neural cell
adhesion molecule and synaptophysin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>We have
demonstrated resistance/response mechanisms by morphoproteomics in two patients
with advanced Ewing's sarcoma.</span><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'> This needs to be analyzed retrospectively
and validated prospectively in a larger dataset to allow more robust
conclusions. Next generaration whole exome sequencing of patients with Ewing's
sarcoma responding to IGF1R based treatment and reverse phase protein array
analysis in patients acquiring resistance is underway and will help to decipher
unidentified mechanisms and perhaps unravel novel mutations and genetic
aberrations in the response and resistance pathways.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Our observations suggest that
rational combinations of targeted therapy, which modulate multiple relevant
pathways, may be useful in overcoming resistance in patients with Ewing's
sarcoma. Inhibition of IGF1R and/or IGF1R and mTOR has resulted in significant
clinical activity in patients with Ewing's sarcoma. Study of an IGF1R inhibitor
combined with mTOR inhibitor is currently underway. Our pilot results suggests
that morphoproteomic assessment of signaling pathway activation in Ewing's
sarcoma merits further investigation as a guide to understanding response and
resistance signatures.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Footnotes</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Competing
Interests: </span></b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>The
authors have declared that no competing interests exist.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Funding: </span></b><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>This
study was funded by in part by U01 CA062461-17 (RK) and NCI-CTEP
R21-CA13763301A1 (AN). This work was also supported by Grant RR024148 from the
National Center for Research Resources (NCRR), National Institutes of Health
(NIH), and NIH Roadmap for Medical Research. Its contents are solely the
responsibility of the authors and do not necessarily represent the official
view of NCRR or NIH. Information on NCRR is available at <a
href="http://www.ncrr.nih.gov/" target="pmc_ext">http://www.ncrr.nih.gov/</a>.
Information on Reengineering the Clinical Research Enterprise can be obtained
from <a
href="http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp"
target="pmc_ext">http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp</a>.
The University of Texas MD Anderson Cancer Center is supported in part by the
NIH through Cancer Center Support Grant no. CA 016672. Presented in part as a
platform presentation at the 16th Annual Meeting of the Connective Tissue
Oncologic Society, November 11-13, 2010, Paris, France. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>References</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>1.
Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol. 2010;11:184192. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/20152770" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>2.
Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, et al. Outcomes for
children and adolescents with cancer: challenges for the twenty-first century.
J Clin Oncol. 2010;28:26252634. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881732/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20404250" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>3.
Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, et al. Ewing's sarcoma:
standard and experimental treatment options. Curr Treat Options Oncol.
2009;10:126140. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/19533369"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>4.
Subbiah V, Anderson PM. Targeted Therapy of Ewing's Sarcoma. Sarcoma.
2010;Volume 2011 (2011) Article ID 686985, doi:10.1155/2011/686985.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>5.
Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art,
and opportunities for targeted therapy in the future. Curr Opin Oncol.
2008;20:412418. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/18525337"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>6.
Rodon J, Perez J, Kurzrock R. Combining targeted therapies: practical issues to
consider at the bench and bedside. Oncologist. 2010;15:3750. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227881/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20080862" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>7.
Brown RE. Morphogenomics and morphoproteomics: a role for anatomic pathology in
personalized medicine. Arch Pathol Lab Med. 2009;133:568579. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/19391654" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>8.
Naing A, Kurzrock R. Chemotherapy resistance and retreatment: a dogma
revisited. Clin Colorectal Cancer. 2010;9:E14. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/20378496" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>9.
Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify
potential therapeutic targets in cancer patients. Expert Rev Proteomics.
2005;2:337348. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16000081"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>10.
Rodon J, DeSantos V, Ferry RJ, Jr, Kurzrock R. Early drug development of
inhibitors of the insulin-like growth factor-I receptor pathway: lessons from
the first clinical trials. Mol Cancer Ther. 2008;7:25752588. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101870/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18790742" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>11.
Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, et al. Phase I,
pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal
antibody to insulin-like growth factor receptor 1. J Clin Oncol.
2009;27:58005807. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/19786654"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>12.
Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, et al. A phase I study of
weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor
antagonist, in patients with advanced solid tumors. Clin Cancer Res.
2010;16:24582465. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/20371689"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>13.
Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, et al. Safety,
pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody
figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase
1 expansion cohort study. Lancet Oncol. 2010;11:129135. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941877/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20036194" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>14.
Maki RG. Small is beautiful: insulin-like growth factors and their role in
growth, development, and cancer. J Clin Oncol. 2010;28:49854995. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039924/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20975071" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>15.
Olmos D, Tan DS, Jones RL, Judson IR. Biological rationale and current clinical
experience with anti-insulin-like growth factor 1 receptor monoclonal
antibodies in treating sarcoma: twenty years from the bench to the bedside.
Cancer J. 2010;16:183194. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/20526094" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>16.
Zenali MJ, Zhang PL, Bendel AE, Brown RE. Morphoproteomic Confirmation of
Constitutively Activated mTOR, ERK, and NF-kappaB Pathways in Ewing Family of
Tumors. Ann Clin Lab Sci. 2009;39:160166. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/19429803" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>17.
Shen Q, Stanton ML, Feng W, Rodriguez ME, Ramondetta L, et al. Morphoproteomic
analysis reveals an overexpressed and constitutively activated phospholipase
D1-mTORC2 pathway in endometrial carcinoma. Int J Clin Exp Pathol.
2010;4:1321. [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016100/">PMC
free article</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/21228924"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>18.
Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, et al. IMC-A12, a
Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor.
Clinical Cancer Research. 2007;13:5549s5555s. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/17875788" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>19.
Wang Y, Lipari P, Wang X, Hailey J, Liang L, et al. A fully human insulin-like
growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor
activity as a single agent and in combination with cytotoxics in pediatric
tumor xenografts. Mol Cancer Ther. 2010;9:410418. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/20124453" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>20.
Rosner M, Hengstschlager M. Cytoplasmic and nuclear distribution of the protein
complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and
delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet.
2008;17:29342948. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/18614546"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>21.
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation
of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:10981101. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/15718470" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>22.
Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, et al. Synergy
between an IGF-1R antibody and Raf//MEK//ERK and PI3K//Akt//mTOR pathway
inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
Leukemia. 2006;20:12541260. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/16642049" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>23.
Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K
cassette induces IRS1/2 depletion, insulin resistance, and cell survival
deficiencies. Curr Biol. 2004;14:16501656. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/15380067" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>24.
Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, et al. Prolonged rapamycin
treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159168. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/16603397" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>25.
Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling
of Ewing cells reveal downstream oncogenic pathways and a crucial role for
repression of insulin-like growth factor binding protein 3. Mol Cell Biol.
2004;24:72757283. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC479730/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15282325" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>26.
Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type
independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's
sarcoma cell proliferation. Oncogene. 2003;22:92829287. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/14681687" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>27.
Galli S, Li G, Tsokos M. Pediatrics. Modern Pathology. 2010;23:393A395A.</span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#__abstractid1066283title">Abstract</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#s1title">Introduction</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#s2title">Methods</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#s3title">Results</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#s4title">Discussion</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#__fn-groupid438816title">Footnotes</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/#__ref-listid751326title">References</a></span></li>
</ul>

<div class=MsoNormal align=center style='margin-bottom:0in;margin-bottom:.0001pt;
text-align:center;line-height:normal'><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal align=center style='margin-bottom:0in;margin-bottom:.0001pt;
text-align:center;line-height:normal'><span lang=EN style='font-size:12.0pt;
font-family:"Arial","sans-serif"'>Articles from PLoS ONE are provided here
courtesy of <b>Public Library of Science</b></span></p>

<p class=MsoNormal>&nbsp;</p>

</div>

</body>

</html>
